| Author/Editor | Ihan, A; Tepeš, B; Gubina, M; Malovrh, T; Kopitar, A | |
| Title | Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients | |
| Type | članek | |
| Source | Hepatogastroenterology | |
| Vol. and No. | Letnik 46, št. 27 | |
| Publication year | 1999 | |
| Volume | str. 1740-5 | |
| Language | eng | |
| Abstract | Background/aims: Helicobacter pylory (H. pylori) infects an estimated 50% of the world population; however, only a small proportion of individuals develop clinical symptoms of gastritis, peptic ulceration of gastric cancer. The variations in disease presentation may be due differences in bacterial virulence and/or immune response to the pathogen. In a previous study we reported and increased expression of the IL-2 receptor in duodenal ulcer (DU) patients. The present study examines the expression of IL-2 receptor and intracellular lymphokine production in gastric mucosa infiltrating T lymphocytes in DU patients before and after H. pylori eradication. Methodology: T lymphocytes were isolated from gastric mucosa biopsies by using mechanical and enzymatic tissue desegregation. Ficoll-purified lymphocytes were incubated with monoclonal antibodies and anlyzed by using 4-color flow cytometry analysis for the IL-2 receptor (CD25) and intracellular interferon-gamma (IFN-gamma) and IL-4 expression. Lymphocytes from 24 H. pylori-infected patients with severe gastric mucosa infiltration (G2 and G3 histological type in Sydney classification) were analyzed. Results: We demonstrated a significant decrease in IL-2 receptor expression on gastric mucosa T cells 3 and 12 months after eradiaction of H. pylori. We also demonstrated a diminished IFN-gamma production 3 and 12 months after H. pylori eradication. Conclusions: Our results suggest that cellular immune activation in gastric mucosa is reversibly dependent on the presence of H. pylori. | |
| Descriptors | GASTRIC MUCOSA DUODENAL ULCER HELICOBACTER INFECTIONS HELICOBACTER PYLORI INTERFERON TYPE I AMOXICILLIN DRUG THERAPY, COMBINATION FLOW CYTOMETRY FOLLOW-UP STUDIES INTERLEUKIN-4 METRONIDAZOLE ORGANOMETALLIC COMPOUNDS RECEPTORS, INTERLEUKIN-2 T-LYMPHOCYTES TREATMENT OUTCOME |